JP2006514067A - 製薬学的安全投薬形態物 - Google Patents

製薬学的安全投薬形態物 Download PDF

Info

Publication number
JP2006514067A
JP2006514067A JP2004566589A JP2004566589A JP2006514067A JP 2006514067 A JP2006514067 A JP 2006514067A JP 2004566589 A JP2004566589 A JP 2004566589A JP 2004566589 A JP2004566589 A JP 2004566589A JP 2006514067 A JP2006514067 A JP 2006514067A
Authority
JP
Japan
Prior art keywords
dosage form
pharmaceutically safe
safe dosage
antagonist
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004566589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514067A5 (enExample
Inventor
ロバーツ，リチヤード・エイチ
Original Assignee
ミユーチユアル・フアーマシユーチカル・カンパニー・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミユーチユアル・フアーマシユーチカル・カンパニー・インコーポレーテツド filed Critical ミユーチユアル・フアーマシユーチカル・カンパニー・インコーポレーテツド
Publication of JP2006514067A publication Critical patent/JP2006514067A/ja
Publication of JP2006514067A5 publication Critical patent/JP2006514067A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2004566589A 2003-01-10 2003-12-18 製薬学的安全投薬形態物 Pending JP2006514067A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/339,977 US7524515B2 (en) 2003-01-10 2003-01-10 Pharmaceutical safety dosage forms
PCT/US2003/040990 WO2004062642A1 (en) 2003-01-10 2003-12-18 Pharmaceutical safety dosage forms

Publications (2)

Publication Number Publication Date
JP2006514067A true JP2006514067A (ja) 2006-04-27
JP2006514067A5 JP2006514067A5 (enExample) 2007-02-08

Family

ID=23331375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004566589A Pending JP2006514067A (ja) 2003-01-10 2003-12-18 製薬学的安全投薬形態物

Country Status (7)

Country Link
US (2) US7524515B2 (enExample)
EP (1) EP1581188A4 (enExample)
JP (1) JP2006514067A (enExample)
AU (1) AU2003299826A1 (enExample)
CA (2) CA2505661C (enExample)
TW (1) TWI265812B (enExample)
WO (1) WO2004062642A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511683A (ja) * 2006-12-04 2010-04-15 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1299104T1 (sl) * 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
WO2003004033A1 (en) * 2001-07-06 2003-01-16 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
WO2003004030A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429730A4 (en) * 2001-09-26 2010-06-16 Penwest Pharmaceuticals Compan OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
EP2359817B1 (en) * 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7513091B2 (en) * 2003-07-30 2009-04-07 Merrion Research Iii Limited Process and machine for automated manufacture of gastro-retentive devices
WO2005018616A1 (en) * 2003-08-12 2005-03-03 Endo Pharmaceuticals, Inc. Method for deterring abuse of opioids by combination with non-release formulation of emetic
AU2013206525B2 (en) * 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ES2324719T3 (es) * 2004-02-23 2009-08-13 Euro-Celtique S.A. Dispositivo de administracion transdermica de opioides con resistencia al abuso.
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
JP2008543851A (ja) * 2005-06-13 2008-12-04 ポール・ローゼンバーグ 催吐剤封入カプセル
US9060950B2 (en) * 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
ES2636657T3 (es) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
EP2380564B1 (en) * 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246265A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
MX2011006173A (es) * 2008-12-12 2011-09-01 Paladin Labs Inc Formulaciones de drogas narcoticas con disminuido potencial de abuso.
CN105213318A (zh) 2009-05-18 2016-01-06 希格默伊德药业有限公司 包含油滴的组合物
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
PT2706986E (pt) 2011-09-19 2015-07-07 Orexo Ab Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN104968333B (zh) 2012-11-30 2018-07-10 阿库拉制药公司 活性药物成分的自调节释放
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3122336A4 (en) 2014-03-26 2017-10-25 Sun Pharma Advanced Research Company Ltd Abuse deterrent immediate release biphasic matrix solid dosage form
DK3215127T3 (da) 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
KR20180012771A (ko) * 2015-05-13 2018-02-06 4피-파마 자극제 남용 억제성 조성물
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN115400092A (zh) * 2021-05-28 2022-11-29 上海博志研新药物技术有限公司 硝苯地平美托洛尔缓释组合物、其制备方法及应用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193835A (ja) * 2000-10-25 2002-07-10 Euro Celtique Sa 経皮的な剤型
JP2003113074A (ja) * 2001-09-17 2003-04-18 Rohm & Haas Co 投薬フォーム
JP2005508372A (ja) * 2001-11-02 2005-03-31 エラン コーポレーシヨン ピーエルシー 薬剤組成物
JP2005520783A (ja) * 2001-08-06 2005-07-14 ユーロ−セルティーク エス．エイ． 治療薬と逆作用剤を含む経口用製剤
JP2006501241A (ja) * 2002-08-20 2006-01-12 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
JP2006506374A (ja) * 2002-10-25 2006-02-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用が防止された製剤

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6091A (en) * 1849-02-06 Improvement in rotary-cutter plows
US35839A (en) * 1862-07-08 Improvement in vegetable-cutters
GB1428361A (en) 1972-02-15 1976-03-17 Grant A Safeguarded medicinal compositions
US4175119A (en) * 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4371539A (en) * 1981-04-27 1983-02-01 American Home Products Corporation CNS Stimulants
US4459278A (en) * 1983-03-07 1984-07-10 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4529583A (en) * 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
GB2162061B (en) 1984-05-03 1988-11-16 Bibhuti B Bardhan Controlled time release therapeutic composition having means for counteracting overdosage
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4981468A (en) * 1989-02-17 1991-01-01 Eli Lilly And Company Delivery device for orally administered therapeutic agents
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9710726D0 (en) * 1997-05-23 1997-07-16 Nycomed Imaging As Compound
ES2203963T3 (es) * 1997-05-30 2004-04-16 Osmotica Corp. Dispositivo osmotico multicapa.
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US20030004177A1 (en) * 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193835A (ja) * 2000-10-25 2002-07-10 Euro Celtique Sa 経皮的な剤型
JP2005520783A (ja) * 2001-08-06 2005-07-14 ユーロ−セルティーク エス．エイ． 治療薬と逆作用剤を含む経口用製剤
JP2003113074A (ja) * 2001-09-17 2003-04-18 Rohm & Haas Co 投薬フォーム
JP2005508372A (ja) * 2001-11-02 2005-03-31 エラン コーポレーシヨン ピーエルシー 薬剤組成物
JP2006501241A (ja) * 2002-08-20 2006-01-12 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
JP2006506374A (ja) * 2002-10-25 2006-02-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用が防止された製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRINICAL TOXICOLOGY, vol. 17(3), JPN6010027894, 1980, pages 353 - 358, ISSN: 0001625528 *
臨床と薬物治療, vol. 21(6), JPN6010027895, 2002, pages 558 - 561, ISSN: 0001625529 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511683A (ja) * 2006-12-04 2010-04-15 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
JP2013249312A (ja) * 2006-12-04 2013-12-12 Orexo Ab オピオイドを含む新規の非−乱用性医薬組成物

Also Published As

Publication number Publication date
EP1581188A4 (en) 2006-04-05
EP1581188A1 (en) 2005-10-05
AU2003299826A1 (en) 2004-08-10
CA2735280A1 (en) 2004-07-29
US20090175950A1 (en) 2009-07-09
WO2004062642A1 (en) 2004-07-29
CA2505661C (en) 2011-06-14
US7919120B2 (en) 2011-04-05
TW200505506A (en) 2005-02-16
US7524515B2 (en) 2009-04-28
US20030124061A1 (en) 2003-07-03
CA2505661A1 (en) 2004-07-29
TWI265812B (en) 2006-11-11
WO2004062642B1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
JP2006514067A (ja) 製薬学的安全投薬形態物
US20230301922A1 (en) Layered Pharmaceutical Formulations
JP6608319B2 (ja) 乱用抵抗性医薬組成物、その使用方法および作製方法
US8911781B2 (en) Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US20080026052A1 (en) Oral Dosage Forms with Therapeutically Active Agents In Controlled Release Cores and Immediate Release Gelatin Capsule Coats
CN101330903A (zh) 防滥用的经黏膜给药装置
US9060950B2 (en) Emetic embedded capsule
WO2014170770A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
CN1838944A (zh) 通过联用催吐剂的非释放制剂阻止阿片样物质滥用的方法
WO2014167437A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
CA2612044C (en) Emetic embedded capsule
US8846084B2 (en) Controlled release compositions containing zolpidem
HK1135026B (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061215

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110315